Ipca Laboratories Ltd. - Research Center
524494 IPCALAB Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sales | 5,814.62 | 5,399.36 | 5,139.16 | 4,367.43 | 3,633.15 |
| Operating profit | 911.85 | 1,243.54 | 1,513.58 | 914.76 | 693.17 |
| Interest | 43.92 | 7.21 | 8.14 | 15.79 | 18.49 |
| Gross profit | 979.12 | 1,292.46 | 1,567.68 | 963.66 | 729.27 |
| EPS (Rs) | 19.93 | 34.33 | 44.97 | 25.82 | 18.00 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Other income | 111.19 | 56.13 | 62.24 | 64.69 | 54.59 |
| Stock adjustment | 104.09 | -120.76 | -170.73 | -155.05 | -106.14 |
| Raw material | 1,684.03 | 1,600.98 | 1,555.53 | 1,431.10 | 1,098.02 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,193.39 | 1,089.63 | 948.84 | 870.79 | 752.24 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,921.26 | 1,585.97 | 1,291.94 | 1,305.83 | 1,195.86 |
| Provisions made | - | - | - | - | - |
| Depreciation | 228.63 | 204.10 | 187.72 | 178.69 | 171.88 |
| Taxation | 244.79 | 217.42 | 239.19 | 132.51 | 102.48 |
| Net profit / loss | 505.70 | 870.94 | 1,140.77 | 652.46 | 454.91 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 25.37 | 25.37 | 25.37 | 25.27 | 25.27 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 15.68 | 23.03 | 29.45 | 20.95 | 19.08 |
| GPM (%) | 16.52 | 23.69 | 30.14 | 21.74 | 19.78 |
| NPM (%) | 8.53 | 15.96 | 21.93 | 14.72 | 12.34 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis